N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI

Phase 2CompletedNCT02791945

University of California, San Francisco30 enrolled

Overview

The goal of the project is to improve the care of Veterans with mild traumatic brain injury (mTBI) and unhealthy alcohol use.

This is a pilot controlled clinical trial that aims to assess the efficacy of N-acetylcysteine (NAC) to reduce alcohol use and improve brain injury symptoms in Veterans with mTBI who consume alcohol at hazardous or harmful levels.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Traumatic Brain Injury (TBI)Hazardous and Harmful Alcohol Use

Interventions

Medical Management CounselingBEHAVIORAL

Brief alcohol counseling

N-acetylcysteineDRUG

Experimental supplement

PlaceboDRUG

Placebo comparator

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male and female veterans 2. Ages 18-65 (inclusive) 3. A history of mTBI as defined by American Congress of Rehabilitation Medicine (ACRM), in the chronic, stable phase of recovery (\>6 months from injury). 4. Current (past month \[30 days\]) Hazardous or Harmful Alcohol Use: Hazardous use is drinking that meets NIAAA criteria: Current (past 30 day) weekly drinking, consisting of an average of 15 standard drinks/week for men or 8 standard drinks/week for women. Harmful use is drinking behavior that meets DSM-5 criteria mild AUD. 5. Participants must express a desire to reduce or stop alcohol use. 6. Female subjects that must have a negative urine pregnancy test and must be either postmenopausal one year or practicing an effective birth control method. Exclusion Criteria: 1. Unstable psychotic or bipolar disorders, dementia, or other psychiatric disorders judged to be unstable in the clinical judgment of the PI or study physician. 2. Clinically significant unstable medical conditions, in the clinical judgment of the PI or study physician. 3. Female patients who are pregnant or nursing. 4. Concurrent participation in another alcohol treatment study, or in any research study involving medications. 5. Requiring acute medical detoxification from alcohol based on a score of 12 or more on the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-AD). 6. NAC use in the past week prior to study entry. 7. Use of AUD treatment medications (disulfiram, naltrexone, or acamprosate) within the past week. 8. Participants who are legally mandated to participate in an alcohol treatment program. 9. Participants who have had a suicide attempt in the past 3 months or suicidal ideation, with intent, in the 30 days prior to enrollment. 10. Participants who in the opinion of the investigator should not be enrolled in the study because of the precautions, warnings or contraindications outlined in the NAC package insert. 11. Participants with known hypersensitivity to acetylcysteine

Locations (1)

San Francisco VA Medical Center

San Francisco, California, United States

Outcomes

Primary Outcomes

Change in Percent of Heavy Drinking Days Per Week as Assessed by the Timeline Followback (TFLB)

The TLFB interview, using a calendar, asks participants to report the prior week's frequency of alcohol use on each day of the week.

Time frame: Baseline to Week 8

Change in TBI Symptoms as Assessed by the Neurobehavioral Symptom Inventory (NSI)

Participants indicate the extent to which each of the 22 symptoms has disturbed them in the previous 2 weeks on a 5-item scale (0-none to 4-severe). The NSI total score is the sum of severity ratings of the symptoms. The scores are summed to yield a total score ranging from 0 to 88, where the higher the point value, the greater (more severe) the symptoms

Time frame: Baseline to Week 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.